Anastrozole

Generic Name
Anastrozole
Brand Names
Arimidex
Drug Type
Small Molecule
Chemical Formula
C17H19N5
CAS Number
120511-73-1
Unique Ingredient Identifier
2Z07MYW1AZ
Background

Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...

Indication

Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...

Associated Conditions
Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
Associated Therapies
-
Clinical Trials
Related News

A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer

First Posted Date
2019-09-03
Last Posted Date
2022-08-10
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
23
Registration Number
NCT04075604
Locations
🇺🇸

The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States

🇺🇸

Hematology-Oncology Associates Of Fredricksburg, Inc, Fredericksburg, Virginia, United States

🇺🇸

MetroHealth Medical Center, Cleveland, Ohio, United States

and more 28 locations

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

First Posted Date
2019-08-16
Last Posted Date
2024-10-22
Lead Sponsor
Sanofi
Target Recruit Count
367
Registration Number
NCT04059484
Locations
🇺🇦

Investigational Site Number : 8040001, Kryvyi Rih, Ukraine

🇬🇷

Investigational Site Number : 3000004, Thessaloniki, Greece

🇧🇷

Hospital de Clinicas de Porto Alegre - HCPA Site Number : 0760001, Porto Alegre, Rio Grande Do Sul, Brazil

and more 106 locations

Breast Cancer Treatment Based on Organ-like Culture

First Posted Date
2019-04-24
Last Posted Date
2019-04-24
Lead Sponsor
Xijing Hospital
Target Recruit Count
300
Registration Number
NCT03925233
Locations
🇨🇳

JingSu, Xi'an, Shaanxi, China

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

First Posted Date
2019-01-30
Last Posted Date
2024-11-27
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
376
Registration Number
NCT03822468
Locations
🇺🇸

Southern Cancer Center PC, Mobile, Alabama, United States

🇺🇸

Rocky Mountain Cancer Centers, Longmont, Colorado, United States

🇺🇸

Nebraska Cancer Specialists, Omaha, Nebraska, United States

and more 12 locations

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

First Posted Date
2018-10-01
Last Posted Date
2023-11-15
Lead Sponsor
Emory University
Target Recruit Count
38
Registration Number
NCT03691493
Locations
🇺🇸

Grady Health System, Atlanta, Georgia, United States

🇺🇸

Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

🇺🇸

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States

and more 7 locations

Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer

First Posted Date
2018-06-14
Last Posted Date
2023-07-07
Lead Sponsor
German Breast Group
Target Recruit Count
56
Registration Number
NCT03555877
Locations
🇩🇪

Studienzentrum Onkologie Ravensburg, Ravensburg, Germany

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

First Posted Date
2018-06-12
Last Posted Date
2023-05-15
Lead Sponsor
University of California, San Francisco
Target Recruit Count
20
Registration Number
NCT03554044
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

First Posted Date
2017-10-06
Last Posted Date
2024-08-01
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
44
Registration Number
NCT03304080
Locations
🇺🇸

Perlmutter Cancer Center NYU Langone, New York, New York, United States

🇺🇸

New York Presbyterian Weill Cornell Medical Center, New York, New York, United States

🇺🇸

New York Presbyterian Columbia Irving Comprehensive Cancer Center, New York, New York, United States

and more 2 locations

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

First Posted Date
2017-09-05
Last Posted Date
2024-04-17
Lead Sponsor
Palleos Healthcare GmbH
Target Recruit Count
257
Registration Number
NCT03272477
Locations
🇩🇪

Evangelisches Krankenhaus Bethesda Mönchengladbach, Mönchengladbach, Germany

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

First Posted Date
2017-08-03
Last Posted Date
2018-12-27
Lead Sponsor
Fred Hutchinson Cancer Center
Registration Number
NCT03238703
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy